Focus on Myeloid Malignancies (Volume 6, Issue 6.1)

May 2020 Special Edition

Volume 6, Issue 6.1

This supplement explores the value of mutation testing for myeloid malignancies, reevaluates maintenance therapy in AML, and more.

Table of Contents

May 2020 Special Edition

Putting Mutation Testing in Myeloid Malignancies to the Test

Friday, May 1st, 2020
In 2014, the World Health Organization (WHO) convened a clinical advisory committee to begin updating and revising the existing classification of myeloid neoplasms (MPNs)...

Emerging Opportunities: Reevaluating Maintenance Therapy in AML

Friday, May 1st, 2020
The concept of maintenance therapy in acute myeloid leukemia (AML) is not new. But for decades, research was unable to show any clear survival...

May 2020 Special Edition

New Research Identifies W491 as a Potential Therapeutic Target in Essential Thrombocythemia

Friday, May 1st, 2020
In patients with familial essential thrombocythemia (ET) negative for JAK2, CALR, or MPL W515 mutation (triple-negative), newly identified MPL mutations elucidate a broad mechanism...

Venetoclax Plus High-Dose Cytarabine With or Without Idarubicin Well Tolerated in Pediatric AML

Friday, May 1st, 2020
In a small study of children and young adults with relapsed or refractory acute myeloid leukemia (AML), venetoclax plus cytarabine chemotherapy, with or without...

Clonal Hematopoiesis, Aberrant CD7 Expression Linked to Post-AHCT Therapy-Related Myeloid Neoplasms

Friday, May 1st, 2020
Low variant allele frequency (VAF) clonal hematopoiesis, aberrant CD7 expression on hematopoietic stem cells, and specific gene mutations at the time of autologous hematopoietic...

Venetoclax Plus Low-Dose Cytarabine Improves Survival and Remission in Patients With Chemotherapy-Ineligible AML

Friday, May 1st, 2020
Treatment with venetoclax plus low-dose cytarabine (LDAC) led to greater improvements in remission and overall survival (OS), compared with LDAC alone, in patients with...

Chk1 Inhibition Shows Efficacy for Splicing Factor Mutant MDS and Leukemia

Friday, May 1st, 2020
A new study found Chk1 inhibition with or without splicing modulators may be an effective targeted treatment approach for splicing factor mutant myelodysplastic syndromes...

2017 European LeukemiaNet Risk Groups Predict Prognosis in FLT3-ITD AML

Friday, May 1st, 2020
Genetic risk groups defined by the 2017 European LeukemiaNet (ELN) recommendations may reliably predict prognosis in patients with acute myeloid leukemia (AML) and internal...

May 2020 Special Edition

On location

MLL Associated With Worse Post-Transplant Outcomes Than Other Cytogenetic Factors

Friday, May 1st, 2020
In an analysis comparing the effects of MLL translocations with other cytogenetic characteristics on post-transplant outcomes in acute myeloid leukemia (AML), investigators found that...